Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Atazanavir (Reyataz®) capsules, co-administered with low dose ritonavir, are recommended as an option for use within NHS Wales for the treatment of HIV-1 infected paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products. Atazanavir (Reyataz®) is not suitable for shared care within NHS Wales for the above indication. |
|||
|
|||
Medicine details |
|||
| Medicine name | atazanavir (Reyataz®) | ||
| Formulation | capsule | ||
| Reference number | 746 | ||
| Indication | Co-administered with low dose ritonavir, for the treatment of HIV-1 infected paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products |
||
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd | ||
| BNF chapter | Infections | ||
| Assessment type | Limited | ||
| Status | Recommended | ||
| Advice number | 1810 | ||
| NMG meeting date | 17/11/2010 | ||
| AWMSG meeting date | 15/12/2010 | ||
| Ratification by Welsh Government | 27/01/2011 | ||
| Date of issue | 03/02/2011 | ||